| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
80.88(B) |
| Last
Volume: |
7,412,694 |
Avg
Vol: |
8,704,124 |
| 52
Week Range: |
$63.43 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,000 |
25,472 |
38,458 |
80,792 |
| Total Sell Value |
$145,920 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
1 |
5 |
9 |
14 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Martin John C |
Executive Chairman |
• • – |
2017-05-01 |
4 |
AS |
$68.31 |
$5,009,429 |
D/D |
(73,333) |
3,126,636 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-05-01 |
4 |
OE |
$21.58 |
$1,582,159 |
D/D |
73,333 |
3,199,969 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-04-03 |
4 |
AS |
$67.07 |
$4,926,287 |
D/D |
(73,333) |
3,126,636 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-04-03 |
4 |
OE |
$21.58 |
$1,582,159 |
D/D |
73,333 |
3,199,969 |
|
- |
|
| Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-03-30 |
4 |
S |
$67.48 |
$337,392 |
D/D |
(5,000) |
117,988 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-03-01 |
4 |
AS |
$70.38 |
$5,161,206 |
D/D |
(73,333) |
3,126,636 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-03-01 |
4 |
OE |
$21.58 |
$1,582,159 |
D/D |
73,333 |
3,199,969 |
|
- |
|
| Moore Nicholas G |
Director |
• • – |
2017-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
173 |
12,055 |
|
- |
|
| Washington Robin L |
EVP, CFO |
• • – |
2017-02-28 |
4 |
GA |
$0.00 |
$0 |
I/I |
11,804 |
121,547 |
|
- |
|
| Washington Robin L |
EVP, CFO |
• • – |
2017-02-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
11,804 |
9,602 |
|
- |
|
| Wilson Gayle E |
Director |
• • – |
2017-02-23 |
4 |
S |
$69.30 |
$1,411,374 |
D/D |
(20,365) |
120,471 |
|
- |
|
| Wilson Gayle E |
Director |
• • – |
2017-02-23 |
4 |
OE |
$20.71 |
$690,512 |
D/D |
33,350 |
140,836 |
|
- |
|
| Milligan John F |
President and CEO |
• • – |
2017-02-23 |
4 |
OE |
$21.58 |
$2,157,500 |
D/D |
100,000 |
1,165,924 |
|
- |
|
| Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-02-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,430 |
122,988 |
|
- |
|
| Washington Robin L |
EVP, CFO |
• • – |
2017-02-16 |
4 |
D |
$70.31 |
$549,402 |
D/D |
(7,814) |
21,406 |
|
- |
|
| Washington Robin L |
EVP, CFO |
• • – |
2017-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,701 |
29,220 |
|
- |
|
| Meyers James R |
EVP Worldwide Commercial Ops |
• • – |
2017-02-16 |
4 |
GA |
$0.00 |
$0 |
I/I |
4,354 |
125,505 |
|
- |
|
| Meyers James R |
EVP Worldwide Commercial Ops |
• • – |
2017-02-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,354 |
2,715 |
|
- |
|
| Meyers James R |
EVP Worldwide Commercial Ops |
• • – |
2017-02-16 |
4 |
D |
$70.31 |
$144,346 |
D/D |
(2,053) |
7,069 |
|
- |
|
| Meyers James R |
EVP Worldwide Commercial Ops |
• • – |
2017-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,183 |
9,122 |
|
- |
|
| Milligan John F |
President and CEO |
• • – |
2017-02-16 |
4 |
D |
$70.31 |
$589,831 |
D/D |
(8,389) |
1,065,924 |
|
- |
|
| Milligan John F |
President and CEO |
• • – |
2017-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
15,035 |
1,074,313 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-02-16 |
4 |
D |
$70.31 |
$1,776,804 |
D/D |
(25,271) |
3,126,636 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,496 |
3,151,907 |
|
- |
|
| Bischofberger Norbert W |
EVP, R&D and CSO |
• • – |
2017-02-16 |
4 |
GA |
$0.00 |
$0 |
I/I |
11,558 |
2,318,407 |
|
- |
|
1105 Records found
|
|
Page 25 of 45 |
|
|
0.85 (1.33%) 
